Atossa Therapeutics, Inc. (BMV:ATOS)

Market Cap	738.43M -68.8%
Revenue (ttm)	n/a
Net Income	-553.57M
EPS	-64.60
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	416
Average Volume	101
Open	91.80
Previous Close	91.80
Day's Range	91.80 - 91.80
52-Week Range	89.00 - 322.50
Beta	n/a
RSI	20.88
Earnings Date	Mar 27, 2026

About Atossa Therapeutics

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Thera...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 15
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: ATOS

Financial Performance

Financial numbers in USD